The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Outcomes with low-intensity venetoclax in NPM1-mutated AML depend on co-mutational profile
Jad Othman, MBBS, University of Sydney, Sydney, Australia and King’s College and Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the outcomes of lower-intensity therapy with venetoclax in patients with NPM1-mutated acute myeloid leukemia (AML). He highlights that co-occurring mutations significantly impact survival, with IDH1 or IDH2 mutations associated with better outcomes and FLT3-ITD and TET2 mutations associated with worse outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
